CD19 and acute lymphoblastic leukemia: The FDA in the US and the EMA in Europe had already approved three CAR-T products for B-cell malignancies that target the CD-19 antigen: (1) Tisagenlecleucel (KYMRIAH), Novartis Pharmaceuticals Corporation, for relapsed B-cell Acute Lymphoblastic Leukemia (ALL) and relapsed or refractory large B cell lymphoma, (2) Axicabtagene Ciloleucel (YESCARTA), Kite Pharma Inc., for relapsed or refractory large B cell lymphoma, and brexucabtagene autoleucel (TECARTUS), Kite Pharma Inc., for the treatment of relapsed or refractory mantle cell lymphoma.